Verona Pharma (NASDAQ:VRNA) Issues Quarterly Earnings Results

Verona Pharma (NASDAQ:VRNA) released its earnings results on Monday. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.12), Zacks reports. The business had revenue of $5.62 million during the quarter, compared to the consensus estimate of $2.31 million. During the same quarter last year, the firm earned ($0.18) EPS.

Verona Pharma Price Performance

VRNA stock traded up $0.85 on Tuesday, reaching $39.00. The company had a trading volume of 79,777 shares, compared to its average volume of 917,849. Verona Pharma has a 1 year low of $11.39 and a 1 year high of $39.38. The company has a debt-to-equity ratio of 0.72, a quick ratio of 8.61 and a current ratio of 8.61. The company’s fifty day moving average is $30.84 and its 200 day moving average is $22.33. The company has a market cap of $3.17 billion, a P/E ratio of -24.77 and a beta of 0.42.

Insider Activity at Verona Pharma

In related news, CFO Mark W. Hahn sold 141,360 shares of the company’s stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of $4.38, for a total value of $619,156.80. Following the sale, the chief financial officer now owns 13,672,560 shares of the company’s stock, valued at approximately $59,885,812.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Verona Pharma news, CEO David Zaccardelli sold 110,456 shares of the business’s stock in a transaction on Monday, October 21st. The stock was sold at an average price of $4.38, for a total value of $483,797.28. Following the completion of the transaction, the chief executive officer now directly owns 14,894,464 shares in the company, valued at approximately $65,237,752.32. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Mark W. Hahn sold 141,360 shares of the business’s stock in a transaction on Thursday, October 24th. The shares were sold at an average price of $4.38, for a total value of $619,156.80. Following the completion of the transaction, the chief financial officer now owns 13,672,560 shares of the company’s stock, valued at $59,885,812.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 868,840 shares of company stock valued at $3,805,519. 4.80% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Truist Financial boosted their target price on Verona Pharma from $38.00 to $44.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Wells Fargo & Company initiated coverage on Verona Pharma in a research report on Thursday, October 3rd. They set an “overweight” rating and a $50.00 target price on the stock. Canaccord Genuity Group boosted their price target on Verona Pharma from $37.00 to $44.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, HC Wainwright boosted their price target on Verona Pharma from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $41.50.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.